Publication Date:
2015-07-10
Description:
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing Cell Death and Disease 6, e1815 (July 2015). doi:10.1038/cddis.2015.187 Authors: Z Wang, P Dove, X Wang, A Shamas-Din, Z Li, A Nachman, Y J Oh, R Hurren, A Ruschak, S Climie, B Press, C Griffin, E Undzys, A Aman, R Al-awar, L E Kay, D O'Neill, S Trudel, M Slassi & A D Schimmer
Electronic ISSN:
2041-4889
Topics:
Biology
,
Medicine
Permalink